4 citations · 8 across the 4 of their papers we have counts for
4 papers
Generating the right evidence at the right time: Principles of a new class of flexible augmented clinical trial designs
Cornelia Dunger-Baldauf, Rob Hemmings, Frank Bretz +3
The past few years have seen an increasing number of initiatives aimed at integrating information generated outside of confirmatory randomised clinical trials (RCTs) into drug deve…
CohortPlat: Simulation of cohort platform trials investigating combination therapies
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +2
Platform trials have gained a lot of attention recently as a possible remedy for time-consuming classical two-arm randomized controlled trials, especially in early phase drug devel…
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +3
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questio…
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials
Kaspar Rufibach, Regina Stegherr, Claudia Schmoor +12
Analyses of adverse events (AEs) are an important aspect of the evaluation of experimental therapies. The SAVVY (Survival analysis for AdVerse events with Varying follow-up times)…